Reuters logo
BRIEF-Revance Therapeutics reports qtrly net loss per share attributable to common stockholders basic and diluted‍​ $1.01
November 2, 2017 / 9:06 PM / a month ago

BRIEF-Revance Therapeutics reports qtrly net loss per share attributable to common stockholders basic and diluted‍​ $1.01

Nov 2 (Reuters) - Revance Therapeutics Inc

* Revance releases third quarter 2017 results

* Revance Therapeutics Inc - ‍sakura 1 & 2 phase 3 pivotal trials on track to report topline results before year-end 2017​

* Revance Therapeutics Inc - ‍expects to complete sakura open-label safety phase 3 study of rt002 injectable for treatment of glabellar lines in h2 2018​

* Revance Therapeutics Inc - ‍reaffirmed financial guidance provided in january 2017​

* Revance Therapeutics Inc qtrly net loss per share attributable to common stockholders basic and diluted‍​ $1.01 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below